Growth-Inhibitory Effects of Traditional Chemotherapeutic Combinations (FOLFOX, FOLFIRI) on Colon Cancer Cells: An in vitro Study

Öz

Objective: To compare the in vitro growth-inhibitory effects of the commonly used chemotherapeutic combinations folinic acid, 5-fluorouracil, and oxaliplatin (FOLFOX) and folinic acid, 5-fluorouracil, and irinotecan (FOLFIRI) on colon cancer cells (HT29 and CaCo-2 cells). Materials and Methods: The viability of HT29 and CaCo-2 cells treated with different concentrations of the FOLFOX and FOLFIRI combinations was evaluated using the MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) assay. Results: FOLFOX and FOLFIRI combinations exhibited varying effects on the colon cancer cell lines, with HT29 cells showing sensitivity, while CaCo-2 cells demonstrated resistance to these treatments. Conclusions: The results of this preliminary study will contribute to the development of effective and targeted clinical treatment strategies for colon cancer.

Anahtar Kelimeler

• Colon cancer
• drug combination
• FOLFOX
• FOLFIRI
• growth-inhibitory effect

Geleneksel Kemoterapötik Kombinasyonların (FOLFOX, FOLFIRI) Kolon Kanseri Hücreleri Üzerindeki Büyüme-Engelleyici Etkileri: Bir in vitro Çalışma

Öz

Amaç: Yaygın olarak kullanılan kemoterapötik kombinasyonlar olan folinik asit, 5-florourasil ve oksaliplatin (FOLFOX) ile folinik asit, 5-florourasil ve irinotekanın (FOLFIRI) kolon kanseri hücreleri (HT29 ve CaCo-2 hücreleri) üzerindeki in vitro büyümeyi inhibe edici etkilerini karşılaştırmak. Materyal ve Metot: FOLFOX ve FOLFIRI kombinasyonlarının farklı konsantrasyonlarıyla tedavi edilen HT29 ve CaCo-2 hücrelerinin canlılığı MTT (3-(4,5-dimetiltiazolil-2)-2,5-difeniltetrazolium bromür) testi kullanılarak değerlendirildi. Bulgular: FOLFOX ve FOLFIRI kombinasyonları kolon kanseri hücre hatları üzerinde farklı etkiler gösterdi, HT29 hücreleri duyarlılık gösterirken, CaCo-2 hücreleri bu tedavilere direnç gösterdi. Sonuç: Bu ön çalışmanın sonuçları, kolon kanseri için etkili ve hedefli klinik tedavi stratejilerinin geliştirilmesine katkıda bulunacaktır.

Anahtar Kelimeler

• Antiproliferatif etki
• FOLFIRI
• FOLFOX
• ilaç kombinasyonu
• kolon kanseri

Kaynakça

1. Gach-Janczak K, Drogosz-Stachowicz J, Janecka A, Wtorek K, Mirowski M. Historical Perspective and Current Trends in Anticancer Drug Development. Cancers. 2024;16(10):1878. doi:10.3390/CANCERS16101878
2. Azwar S, Seow HF, Abdullah M, Jabar MF, Mohtarrudin N. Recent Updates on Mechanisms of Resistance to 5-Fluorouracil and Reversal Strategies in Colon Cancer Treatment. Biology. 2021;10(9):854. doi:10.3390/BIOLOGY10090854
3. Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5(1):1-30. doi:10.1038/s41392-020-0116-z
4. Liu X, Ou K, Ma X, et al. Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study. BMC Cancer. 2022;22(1):807. doi:10.1186/S12885-022-09889-3
5. Ashique S, Bhowmick M, Pal R, et al. Multi drug resistance in Colorectal Cancer- approaches to overcome, advancements and future success. Adv Cancer Biol - Metastasis. 2024;10:100114. doi:10.1016/J.ADCANC.2024.100114
6. Narayan S, Raza A, Mahmud I, et al. Sensitization of FOLFOX-resistant colorectal cancer cells via the modulation of a novel pathway involving protein phosphatase 2A. iScience. 2022;25(7). doi:10.1016/J.ISCI.2022.104518
7. Sethy C, Kundu CN. 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition. Biomed Pharmacother. 2021;137: 111285. doi:10.1016/J.BIOPHA.2021.111285
8. Glimelius B, Stintzing S, Marshall J, Yoshino T, de Gramont A. Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone. Cancer Treat Rev. 2021;98:102218. doi:10.1016/J.CTRV.2021.102218

9. Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. Pharmacol Ther. 2020;206:107447. doi:10.1016/J.PHARMTHERA.2019.107447
10. Chai Y, Liu JL, Zhang S, et al. The effective combination therapies with irinotecan for colorectal cancer. Front Pharmacol. 2024;15:1356708. doi:10.3389/FPHAR.2024.1356708/BIBTEX
11. Kumar S, Sherman MY. Resistance to TOP-1 Inhibitors: Good Old Drugs Still Can Surprise Us. Int J Mol Sci. 2023;24(8):7233. doi:10.3390/IJMS24087233
12. Amniouel S, Jafri MS. High-accuracy prediction of colorectal cancer chemotherapy efficacy using machine learning applied to gene expression data. Front Physiol. 2023;14:1272206. doi:10.3389/FPHYS.2023.1272206
13. Bilgin S, Erden Tayhan S, Yıldırım A, Koç E. Investigation of the effects of isoeugenol-based phenolic compounds on migration and proliferation of HT29 colon cancer cells at cellular and molecular level. Bioorg Chem. 2023;130:106230. doi:10.1016/J.BIOORG.2022.106230
14. Galateanu B, Hudita A, Negrei C, et al. Impact of multicellular tumor spheroids as an in vivo-like tumor model on anticancer drug response. Int J Oncol. 2016;48(6):2295. doi:10.3892/IJO.2016.3467
15. Biller LH, Schrag D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA. 2021;325(7):669-685. doi:10.1001/JAMA.2021.0106
16. Pathak PS, Chan G, Deming DA, Chee CE. State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation. https://doi.org/101200/EDBK_438466. 2024;44(3). doi:10.1200/EDBK_438466
17. Wanes D, Naim HY, Dengler F. Proliferation and Differentiation of Intestinal Caco-2 Cells Are Maintained in Culture with Human Platelet Lysate Instead of Fetal Calf Serum. Cells. 2021;10(11):3038. doi:10.3390/CELLS10113038
18. Zoetemelk M, Ramzy GM, Rausch M, Nowak-Sliwinska P. Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment. Molecules. 2020;25(11):2614. doi:10.3390/MOLECULES25112614
19. Machover D, Almohamad W, Castagné V, Desterke C, Gomez L, Goldschmidt E. Treatment of patients with carcinomas in advanced stages with 5-fluorouracil, folinic acid and pyridoxine in tandem. Sci Rep. 2024;14(1):12054. doi:10.1038/S41598-024-62860-Z
20. Budithi A, Su S, Kirshtein A, Shahriyari L. Data Driven Mathematical Model of FOLFIRI Treatment for Colon Cancer. Cancers. 2021;13(11):2632. doi:10.3390/CANCERS13112632
21. Gagnon M, Zihler Berner A, Chervet N, Chassard C, Lacroix C. Comparison of the Caco-2, HT-29 and the mucus-secreting HT29-MTX intestinal cell models to investigate Salmonella adhesion and invasion. J Microbiol Methods. 2013;94(3):274-279. doi:10.1016/J.MIMET.2013.06.027
22. Gmeiner WH. Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment. Cancers (Basel). 2024;16(5):1029. doi:10.3390/CANCERS16051029
23. Gu J, Li Z, Zhou J, Sun Z, Bai C. Response prediction to oxaliplatin plus 5-fluorouracil chemotherapy in patients with colorectal cancer using a four-protein immunohistochemical model. Oncology Letters. 2019;18(2):2091-2101. doi:10.3892/OL.2019.10474
24. Lenaerts K, Bouwman FK, Lamers WH, Renes J, Mariman EC. Comparative proteomic analysis of cell lines and scrapings of the human intestinal epithelium. BMC Genomics. 2007;8:1-14. doi:10.1186/1471-2164-8-91
25. Haddad MJ, Sztupecki W, Delayre-Orthez C, et al. Complexification of In Vitro Models of Intestinal Barriers, A True Challenge for a More Accurate Alternative Approach. International Journal of Molecular Sciences. 2023;24(4):3595. doi:10.3390/IJMS24043595
26. Slaninová V, Heron-Milhavet L, Robin M, et al. The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells. BMC Cancer. 2024;24(1):1-18. doi:10.1186/S12885-024-12316-4/FIGURES/6
27. Cerbone A, Toaldo C, Minelli R, et al. Rosiglitazone and AS601245 Decrease Cell Adhesion and Migration through Modulation of Specific Gene Expression in Human Colon Cancer Cells. PLoS One. 2012;7(6):e40149. doi:10.1371/JOURNAL.PONE.0040149
28. Ramzy GM, Boschung L, Koessler T, et al. FOLFOXIRI Resistance Induction and Characterization in Human Colorectal Cancer Cells. Cancers. 2022;14(19):4812. doi:10.3390/CANCERS14194812